Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book provides a complete overview of the latest progress in the field, recent advances and the challenges that remain in developing these highly pathogenic agents.

Description based upon print version of record. 5.4.3 Clinical Evaluation of Passive Immunization during the 2013-2016 West Africa Outbreak and the 2018-2020 DRC Outbreak.

Intro -- Title -- Copyright -- Contents -- Chapter 1 Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets -- 1.1 Introduction -- 1.2 Viral Targets for Antiviral Drugs -- 1.2.1 Viral Polymerases -- 1.2.2 Viral Integrase -- 1.2.3 Viral Proteases -- 1.2.4 Structural Proteins -- 1.2.5 Accessory Proteins -- 1.3 Host Targets for Antiviral Drugs -- 1.3.1 Host Chemokine Receptors -- 1.3.2 Host Glycoproteins -- 1.3.3 Host Kinases -- 1.3.4 Other Host Proteins -- 1.4 Viral Versus Host Targets -- 1.4.1 Strengths and Weaknesses of Viral Targets. 1.4.2 Strengths and Weaknesses of Host Targets -- 1.5 Conclusion -- Conflicts of Interest -- Acknowledgements -- References -- Chapter 2 Advances in Prophylaxis and Therapy of Arenavirus Hemorrhagic Fevers -- 2.1 Introduction -- 2.2 Therapeutic Approaches Against Arenaviruses -- 2.2.1 Immunotherapeutic Approaches -- 2.2.2 Antivirals -- 2.3 Prophylaxis of Arenavirus Infections -- 2.4 Concluding Remarks -- References -- Chapter 3 Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic1 -- 3.1 Origin of the COVID-19 Pandemic Produced by SARS-CoV-2 3.2 Coronavirus and Zoonotic Risk -- 3.3 Human Coronaviruses -- 3.4 Structure and Genomic Organization of SARS-CoV-2 -- 3.5 Mechanism of Infection and Pathogenesis of SARS-CoV-2 -- 3.6 Diagnosis and Kinetics of Respiratory Infection by SARS-CoV-2 -- 3.7 The Immune Response to SARS-CoV-2 -- 3.8 Vaccine Development for COVID-19 -- 3.9 Monoclonal Antibodies Against SARS-CoV-2 for COVID-19 Treatment -- 3.10 Antiviral Development for SARS-CoV-2/COVID-19 -- References -- Chapter 4 Small-molecule and Synthetically Derived Antivirals for Ebola Virus and Other Filoviruses1 -- 4.1 Introduction Chapter 5 Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies -- 5.1 Introduction -- 5.2 Introduction to Filoviruses -- 5.2.1 Role of Abs in Natural Infection -- 5.2.2 Role of Abs in Understanding Outbreaks -- 5.2.3 Antibody-dependent Enhancement -- 5.3 The Role of Abs Generated by Experimental Vaccines -- 5.4 Development of Antibodies for Filovirus Medical Countermeasures -- 5.4.1 EBOV mAb Countermeasures -- 5.4.2 Non-EBOV Filoviruses and pan-Ebolavirus mAbs in NHPs